Proactive monitoring vs. standard use of biologics for psoriasis
Part of Skin clinical trials.
This study compares a proactive approach (adjusting drug levels based on regular blood tests) versus the usual way of using biologics for psoriasis. It helps see if active monitoring can improve treatment while keeping you safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of plaque psoriasis from a dermatologist.
- You've been taking secukinumab, ixekizumab, or guselkumab for at least 6 months.
- You are not taking a biologic mainly for another condition like arthritis.
- You are not on other immune-suppressing drugs (except methotrexate or acitretin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures brodalumab levels in your blood to see whether “therapeutic drug monitoring” can guide treatment in people with plaque psoriasis. If you’re eligible, it may help doctors better match the medicine to your body.
This trial tests a new systemic therapy for severe plaque psoriasis and uses skin imaging (dermoscopy) to track improvements. It aims to see how well the treatment works and how it affects your quality of life.
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
This study looks at patients with moderate-to-severe psoriasis who have already responded well to secukinumab (an injection that targets the immune system). Researchers want to see which maintenance dosing schedule works best long-term and causes the fewest side effects.
This study looks at skin cells at the single-cell level to predict which psoriasis treatments will work best for you. It may help doctors personalize treatment choices for plaque psoriasis.
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
Hear when a new Psoriasis Vulgaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.